Plain-English translation of NCT05749276 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing daratumumab, a medication that works by targeting a specific protein on leukemia cells, combined with standard chemotherapy drugs. Researchers want to find the right dose of daratumumab to use safely alongside chemotherapy in older adults with a type of blood cancer called acute myeloid leukemia that carries a high risk of returning or being difficult to treat. The study will help doctors understand whether this combination can help patients live longer and healthier lives.
Older adults with aggressive forms of acute myeloid leukemia have limited treatment options, and many do not survive long after diagnosis. This trial exists to see if adding this medication to standard chemotherapy might improve outcomes by attacking the cancer in a new way.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy drugs (idarubicin and cytarabine, or a combination called CPX-351) as you normally would, and the medication being tested would be added at increasing doses across three dose levels. Depending on which dose level you are assigned to, you would receive the medication once, twice, or three times during your treatment cycle. Your doctor will closely monitor how you respond and watch for any side effects throughout the study to determine the safest and most effective dose.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
France